尿核基质蛋白22诊断膀胱癌的临床评价

目的：分析比较尿核基质蛋白22(NMP22)检测与尿胱落细胞学检查诊断膀胱移行细胞癌的临床价值。方法：对126例临床怀疑膀胱癌的病人，在膀胱镜检查前留取新鲜自排尿，分别进行NMP22检测和脱落细胞学检查，比较2种方法的敏感性、特异性和阳性预测值。结果：126例中病理征实膀胱移行细胞癌35例，其他疾病9l例。NMP22诊断膀胱癌敏感性82．9％，与细胞学(25．7％)比较，差别有权显著性意义(P＜0．01)。即使对浅表性膀胱癌，NMP22的敏感性也达到77.8％，明显优于细胞学的ll.3％(P＜0．01)。2种方法诊断特异性分别为79．1％和100.0％。阳性预测值分别为60.4％和100．0％。结论：NMP22检测是一种简单、敏感的早期诊断膀胱癌的方法。

CLINICAL EVALUATION OF NUCLEAR MATRIX PROTEIN 22 (NMP22) IN URINE AS A MARKER FOR DIAGNOSING BLADDER TRANSITIONAL CELL CARCINOMA

Objective:To evaluate the diagnostic value of urinary NMP22 and cytology in the detection of bladder transitional cell carcinoma.Methods:One hundred and twenty-six sympotomatic patients suspicious of bladder cancer were asked to take urinary NMP22 and cytological examination before cytoscopy.Results:Thirty-five patients were pathologically diagnosed as transitional cell carcinoma,and 91 cases were other urological conditions.The sensitivity of NMP22 (82.9%) was significantly better than urinary cytology (25.7%) , P <0.01.For superficial bladder cancer, the sensitivity of NMP22 was also better than cytology(77.8% versus 11.3%, P <0.01).The specificity of NMP22 and cytology was 79.1% and 100.0%,with the positive predictive values 60.4% and 100.0%.Conclusions:Urinary NMP22 value is a simple ,sensitive and early diagnositic marker for bladder transitional cell carcinoma.